Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1 Endocrine 1

Conditions

Glioblastoma 154 Brain Neoplasms 73 Glioma 69 Central Nervous System Neoplasms 50 Gliosarcoma 46 Astrocytoma 37 Melanoma 36 Oligodendroglioma 29 Neuroblastoma 17 Neoplasm Metastasis 14 Carcinoma, Non-Small-Cell Lung 12 Lung Neoplasms 11 Sarcoma, Ewing 10 Sarcoma 10 Neoplasms 10 Medulloblastoma 10 Recurrence 9 Neuroendocrine Tumors 9 Lymphoma 8 Ependymoma 8 Breast Neoplasms 8 Small Cell Lung Carcinoma 7 Rhabdomyosarcoma 7 Diffuse Intrinsic Pontine Glioma 7 Colorectal Neoplasms 7 Carcinoma, Neuroendocrine 6 Adenoma, Islet Cell 6 Uveal Melanoma 5 Spinal Cord Neoplasms 5 Pheochromocytoma 5

Interventions

epigallocatechin gallate 2 Ascorbic Acid 2 peflavit 1 microcrystalline cellulose 1 fisetin 1 cabozantinib 1 Temozolomide 1 Quercetin 1 Protons 1 Photons 1 Flavonoids 1 Dasatinib 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Frailty × Temozolomide × Clear all

NCT05554003 2024-11-18

MeTe

European Institute of Oncology

Phase 2 Recruiting

Frailty, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon ⚡